For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.

Amgen - Recent Press Releases
10/28/14Amgen Outlines Strategy, Growth Objectives And Capital Allocation PlansPrinter Friendly Version
10/27/14Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30Printer Friendly Version
10/23/14Amgen To Webcast 2014 Business Review Meeting On October 28Printer Friendly Version
10/23/14Amgen Announces Webcast of 2014 Third Quarter Financial ResultsPrinter Friendly Version
10/21/14Amgen Statement Regarding Third Point InvestmentPrinter Friendly Version
10/17/14Amgen Announces Appointment Of R. Sanders Williams To Board Of DirectorsPrinter Friendly Version
10/17/14Amgen Announces 2014 Fourth Quarter DividendPrinter Friendly Version
10/17/14Amgen Files Lawsuit Against Sanofi And Regeneron For Patent InfringementPrinter Friendly Version
10/09/14Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic LeukemiaPrinter Friendly Version
10/08/14Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque PsoriasisPrinter Friendly Version